NCT04633122 2026-04-03
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
Clinical Trials
40 trialsNCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT02401815 2025-02-14
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Completed
NCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
NCT02282059 2024-06-20
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Pfizer
Completed
NCT00716820 2023-04-06
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Pfizer
Completed
NCT01164202 2022-03-18
SATURNE
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT02164240 2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02402062 2020-07-27
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT01396148 2019-03-27
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT00891878 2018-07-24
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00787787 2017-06-01
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
University of Washington
Phase 2 Terminated
NCT00524316 2017-05-09
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00702884 2017-03-21
Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00730353 2017-03-16
Sutent + Taxol for Advanced Esophageal Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00444795 2017-02-01
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
Pfizer
Completed
NCT01054911 2016-09-22
Evaluation of Patients With Bulky GIST Using Sunitinib
University of Alabama at Birmingham
Phase NA Terminated
NCT00793871 2015-11-20
GIST
Pfizer
Phase 4 Completed
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00226811 2015-03-30
An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy
Pfizer
Phase 2 Completed
NCT00457691 2015-03-30
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
Pfizer
Phase 3 Completed
NCT00553696 2015-03-13
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
Pfizer
Phase 1 Completed
NCT00555620 2013-01-14
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT00699374 2013-01-14
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Pfizer
Phase 3 Terminated
NCT00609622 2012-10-11
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00400569 2012-08-28
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed
NCT00495625 2012-03-27
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00555672 2011-12-19
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT00668863 2011-10-17
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
Pfizer
Phase 2 Completed
NCT00372567 2011-03-17
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Pfizer
Phase 3 Terminated
NCT00631410 2011-03-16
Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
Pfizer
Phase 1 Completed
NCT00411151 2011-01-20
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT00428597 2010-10-11
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
Pfizer
Phase 3 Terminated
NCT00247676 2010-02-18
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
Pfizer
Phase 2 Completed
NCT00457743 2009-11-13
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Pfizer
Phase 1/2 Completed
NCT00075218 2009-09-28
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Pfizer
Phase 3 Completed
NCT00137449 2009-09-15
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed